Company Analysis Oncolytics Biotech Inc.
1. Summary
Advantages
- Price (0.9305 $) is less than fair price (1.59 $)
- The stock's return over the last year (-24.85%) is higher than the sector average (-44.93%).
Disadvantages
- Dividends (0%) are below the sector average (0.5526%).
- Current debt level 1.09% has increased over 5 years from 0%.
- The company's current efficiency (ROE=-100.69%) is lower than the sector average (ROE=9.61%)
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
| Oncolytics Biotech Inc. | Healthcare | Index | |
|---|---|---|---|
| 7 days | -2.4% | -17.5% | -2.7% |
| 90 days | 20.4% | -43.2% | 7.6% |
| 1 year | -24.8% | -44.9% | 30.9% |
ONCY vs Sector: Oncolytics Biotech Inc. has outperformed the "Healthcare" sector by 20.09% over the past year.
ONCY vs Market: Oncolytics Biotech Inc. has significantly underperformed the market by -55.76% over the past year.
Stable price: ONCY is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: ONCY with weekly volatility of -0.4779% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Below fair price: The current price (0.9305 $) is lower than the fair price (1.59 $).
Price significantly below the fair price: The current price (0.9305 $) is 70.9% lower than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (0) is lower than that of the sector as a whole (48.77).
P/E vs Market: The company's P/E (0) is lower than that of the market as a whole (48.3).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (4.16) is lower than that of the sector as a whole (4.82).
P/BV vs Market: The company's P/BV (4.16) is higher than that of the market as a whole (3.36).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (0) is lower than that of the sector as a whole (33.76).
P/S vs Market: The company's P/S indicator (0) is lower than that of the market as a whole (10.18).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-2.5) is higher than that of the sector as a whole (-22.31).
EV/Ebitda vs Market: The company's EV/Ebitda (-2.5) is lower than that of the market as a whole (28.27).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -7.82% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-7.82%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-9.16%).
5.4. ROE
ROE vs Sector: The company's ROE (-100.69%) is lower than that of the sector as a whole (9.61%).
ROE vs Market: The company's ROE (-100.69%) is lower than that of the market as a whole (10.79%).
5.5. ROA
ROA vs Sector: The company's ROA (-71.49%) is lower than that of the sector as a whole (0.3359%).
ROA vs Market: The company's ROA (-71.49%) is lower than that of the market as a whole (6.51%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (7.63%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (10.79%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.5526%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
